Treatment effectiveness, compliance and cardiovascular outcomes with a new supine avoidance therapy for supine-predominant snoring.

Not Applicable

Recruiting

• Conditions: Snoring; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12612000699864
• Lead Sponsor: A/Prof Peter Catcheside

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Snorer:
- Age > or = 18 years
- History of disruptive supine-mainly or supine-only snoring
- Home sleep study confirmed supine-predominant snoring (supine > or = twice non-supine snoring frequency measured from at least 4 hours of recording with at least 30 min in each posture condition)
- AHI < 15 /hr from a home screening study (i.e. to rule out clinically significant OSA).
- Willing to cease any current anti-snoring treatment (e.g. over the counter anti-snoring sprays, nasal dilator strips, tennis ball or other discomfort based supine avoidance treatments etc).

Bed-Partner:
- Regular bed partner (defined as present > or = 5 nights/week) of the snorer participant
- Age > or = 18 years

Exclusion Criteria

- Obstructive Sleep Apnoea (Apnoea Hypopnoea Index > or = 15 /hr)
- Co-morbidities that may preclude supine-avoidance treatment (e.g. arthritis, mobility problems preventing non-supine sleep, or a pacemaker given unknown effects of an electronic device in close proximity on the chest)
- Severe oxygen desaturation in sleep (minimum blood oxygen saturation less than 75% during home screening sleep study)
- Sleepiness potentially dangerous and requiring urgent treatment (e.g. history of falling asleep while driving, or Epworth Sleepiness Scale >16) or commercial drivers
- Already on treatment for hypertension

Study & Design

• Study Type: Interventional
• Study Design: Not specified